Eli Lilly and Company will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for the acute treatment of migraine. The webcast will begin at 10 a.m. Eastern time. The phase 3 data will also be presented at the 59th Annual Scientific Meeting of the American Headache Society.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.